- Result:
    - Number:

| Indacaterol+tiotropium | Placebo+tiotropium |
|:---|:---|
| 572 | 570 |

    - Differences between indacaterol+tio vs. tio+placebo:
        - FEV₁ AUC 5 min~8 h: 130 mL (90~160)
        - COPD severity:
            - moderate: 110 mL (80~140)
            - severe: 140 mL (110~170)
        - Smoking status:
            - ex smoker: 90 mL (50~120)
            - current smoker: 140 mL (100~170)
        - ICS use:
            - non-users: 100 mL (70~140)
            - users:

    - Trough FEV₁:
        - COPD severity:
            - moderate: 90 mL (60~120)
            - severe: 60 mL (30~90)
        - Smoking status:
            - ex smoker: 80 mL (60~110)
            - current smoker: 60 mL (20~90)
        - ICS use:
            - non-users: 90 mL (60~120)
            - users: 60 mL (30~90)

    - Patient reported symptoms and use of as-needed salbutamol:

| | Indacaterol+tiotropium | Placebo+tiotropium |
|:---|:---|:---|
| Change from baseline symptom score (full 24 h) | -2,2 (0,21) | -1,5 (0,21) |
| Change from baseline symptom score (day-time) | -1,1 (0,12) | -0,8 (0,12) |
| Change from baseline symptom score (night-time) | -1,0 (0,12) | -0,7 (0,12) |
| Change from baseline salbutamol use (puff/day) | -2,1 (0,17) | -1,4 (0,17) |
| Days during treatment with no salbutamol use (%) | 38,7 (1,94) | 33,6 (1,92) |
| Adverse events (%) | | |
| Cough | 9,1 | 4,4 |
| Muscle spasm | 0,3 | 1,1 |
| Plasma potassium <3,5 mmol/L | 1,6 | 1,4 |
| Systolic BP-high | 0,7 | 0,4 |
| QTc interval (absolute value) | 1,8 | 2,6 |

*post-salbutamol for FEV₁ % and FEV₁/FVC and pre/post salbutamol for reversibility

## 9) 경구스테로이드의 장기간 단독 사용은 권장하지 않는다(근거수준: 높음, 권고강도: 강함).

### 근거표 9; Oral corticosteroids

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
|:---|:---|:---|:---|:---|:---|:---|:---|
| 24 | 무작위대조군연구 | 없음 | 없음 | 없음 | 없음 | 없음 | 높음 |

**PICO 및 근거표**

- Author, year publication: Walters JAE, Cochrane Database of Systemic Review 2009
- Title: Oral corticosteroids for stable chronic obstructive pulmonary disease
- Search methods: A search of the Cochrane Airways Group Specialised Register of COPD trials was carried out using the terms: glucocorticoid* or hydroxycorticosteroid* or anti-inflammator* or steroid* or corticosteroid* or prednisone or prednisolone or methylprednisolone or dexamethasone or cortisone or hydrocortisone* or medrol or solumedrol or solu-medrol A additonal search of MEDLINE was carried out using the terms: (COPD OR emphysema OR COAD OR chronic obstructive pulmonary disease OR chronic obstructive airways disease OR chronic bronchitis) AND ("adrenal cortex hormone*" OR steroid* OR glucocorticoid* OR corticosteroid* OR betamethasone OR cortisone OR dexamethasone OR hydrocortisone OR prednisolone OR prednisone OR methylprednisolone OR methylprednisone OR triamcinolone OR hydroxycorticosteroid* OR anti-inflammator* OR "anti inflammator*").
- N: 24 RCT studies
- Aim: To assess the effects of oral corticosteroids on the health status of patients
- Type of studies: Randomised, placebo controlled prospective studies, single or double blind, parallel group or crossover
- Type of participants: In adults with stable COPD, post-bronchodilator FEV₁<80% predicted and FEV₁/FVC<0,7 and a history of smoking
- Exclusion: Known asthmatics
- Type of intervention:
    - Oral steroid vs placebo
    - Corticosteroid administered orally on a daily or alternate-day regimen for a minimum duration of one week
- Type of outcome measures:
    - 1st outcome; changes in FEV₁, and Health related QOL
    - 2nd outcome
    - Proportion of patients who are responders to therapy
    - Acute exacerbation of COPD
    - Symptom severity
    - Functional capacity
    - Adverse effects of medications
    - Outcome analysis was stratified into short-term use (steroid for less than 6 weeks) and long-term use (steroid for 6 weeks or more), low dose or high dose oral steroid use, concomitant inhaled corticosteroid use and severity of disease
- Results: No evidence to support the long-term use of oral steroids at doses less than 10~15 mg prednisolone though some evidence that high (≥30 mg prednisolone) improve lung function over a short period. Potentially harmful adverse effects e.g. diabetes, hypertension, osteoporosis would prevent recommending long-term use at these high doses in most patients.

<PAGE>124